Genetic Signatures signs up
Wednesday, 22 October, 2008
Privately held Sydney biotech Human Genetic Signatures has signed a licensing agreement with US diagnostics specialist ProGen Tech to develop assays for pathogens such as MRSA and Clostridium difficile.
The assays will be integrated into ProGen Tech’s Entura nucleic acid purification system.
Human Genetic Signatures’ technology is called 3base, which is designed to simplify the genomes of microbial targets to aid detection. The company has also developed a DNA methylation analysis methodology called MethylEasy.
ProGen Tech hopes to present manual assays to the US FDA next year, followed by a fully automated version in 2010.
The equipment is aimed at the molecular and clinical diagnostics markets.
Real-time sequencing helps combat golden staph infections
Tracking bacterial changes during serious Staphylococcus aureus (golden staph) infection...
Single-cell sequencing capability boosted in South Australia
The South Australian Genomics Centre has become the first certified service provider in...
Biomaterial helps to reverse aging in the heart
The discovery could open the door to therapies that rejuvenate the heart by changing its cellular...
